New promising potential in fighting atherosclerosis: HDL and reverse cholesterol transport

Area of Science:

• Cardiovascular Science
• Lipid Metabolism
• Public Health

Background:

• Atherogenesis and cardiovascular disease (CVD) mortality represent a major global health challenge, exacerbated by rising obesity rates in developing nations.
• Statins effectively lower low-density lipoprotein (LDL) cholesterol but leave a substantial residual CVD risk.
• Low high-density lipoprotein (HDL) cholesterol is an independent risk factor for CVD.

Purpose of the Study:

• To explore the role of HDL in anti-atherogenesis beyond simple cholesterol transfer.
• To identify therapeutic strategies for increasing HDL levels to complement statin therapy.

Main Methods:

• Review of recent studies on HDL function in cholesterol efflux from foam cells.
• Analysis of the association between HDL levels and CVD risk.
• Examination of therapeutic interventions targeting HDL.

Main Results:

• The role of HDL in preventing atherosclerosis is more complex than previously thought, involving direct cholesterol removal from foam cells.
• Low HDL levels are consistently linked to increased CVD risk.
• Targeting HDL-raising therapies is a promising strategy to mitigate residual CVD risk.

Conclusions:

• Increasing HDL cholesterol levels is a critical therapeutic goal for reducing residual cardiovascular risk.
• Novel interventions aimed at boosting HDL function are needed to enhance statin efficacy.
• Addressing HDL deficiency is essential for comprehensive CVD prevention strategies.